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Abstract Clinical oncologists have not been paying
enough attention to the fact that poor tumor penetration
represents a major impediment to the efficiency of cancer
chemotherapeutics. The cytokine tumor necrosis factor
(TNF) was the first treatment shown to affect tumor vessel
destruction and improve vascular permeability of drugs in a
clinical setting. TNF produces an early increase of vessel
permeability followed by a dual targeting: TNF induces
apoptosis of intratumoral angiogenic endothelial cells and
melphalan during the apoptosis of tumor cells. Given the
systemic toxicity, TNF has to be administered by regional
therapy. However, experimental data indicate that a
systemic approach will be possible, thanks to TNF
targeting. Three fusion proteins with TNF were shown to
target tumors: anti-EDB fibronectin/TNF, Asn-Gly-Arg-
TNF, and anti-gp240/TNF. Current approaches to blocking
angiogenesis include strategies that target vascular endo-
thelium growth factor (VEGF)-A. However, little attention
has been paid to possible drawbacks, which may include
vessel destruction and reduced penetration by chemother-
apeutic agents administered simultaneously or subse-
quently. An antiangiogenic treatment is optimal when it
is given at a critical dose and at a critical time. Current
protocols seem not to take these prerequisites into
consideration. Other new approaches to increased tumor
vessel permeability include histamine and combretastatin
analog. The current paradigm of antitumor strategy based
on the synergism of empirical drug combinations is
obsolete. Instead, the design of protocols based on new
pharmacodynamic concepts should provide better effi-
ciency of cancer treatment as exemplified in the use of TNF
and anti-VEGF antibody.
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Introduction
A quick survey of the literature shows that little funda-
mental progress in cancer chemotherapy has been achieved
over the last 20 years. This unfortunate state of affairs may
reflect the complexity of the tumor environment and our
failure to target both cancer cells and their associated
stroma that includes angiogenic vessels. Although the idea
of the cancer cell as a “seed” that can only develop if it is
supported by a good “soil” (the stroma with connective
tissue and angiogenic vessels) is an old one (see recent
retrospective by Fidler [1]), traditional therapies fail to
account for the fact that anticancer agents must pass
through the soil before they can destroy the seed. Thus, for
a long time, clinical oncologists were not paying enough
attention to the fact that poor tumor penetration represents a
major impediment to the efficiency of cancer chemother-
apeutics. A typical example is the lack of penetration of
doxorubicin [2] as illustrated by its detection by fluores-
cence in the tissues (Fig. 1). The pioneering work of R. Jain
[3] shed a new light on tumor vascularization and fluid
biology. It shows that the major impediments to drug
penetration in tumors are the lack of permeability and the
increased interstitial pressure. It is possible to reverse the
situation by acting on endothelial cells in the angiogenic
vessels. The two most explored ways to do so are the use of
the cytokine tumor necrosis factor (TNF) and antivascular
endothelium growth factor (VEGF) strategies.
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TNF-α
The cytokine TNF was the first treatment shown to affect
tumor vessel destruction and improve vascular permeabil-
ity of drugs in a clinical setting [4, 5]. The cytokine was
named after its property to produce hemorrhagic necrosis in
experimental tumors but the clinical application of TNF as
systemic treatment was rapidly abandoned because it exerts
only a relatively weak antitumor effect and because as a
mediator of septic shock, it is poorly tolerated.
To circumvent this problem, in 1988, we had the idea of
using high-dose TNF in isolated limb perfusion (ILP) in
combination with chemotherapy for locally advanced
melanomas and sarcomas of the limbs. ILP consists of
the surgical isolation of the limb vasculature connected to a
heart–lung machine, allowing the continuous circulation of
high doses of cytotoxic agents over a short period of time
(90 min). After perfusion, the vascular space is extensively
rinsed and the vasculature reestablished (reviewed in [6,
7]). Our protocol (Fig. 2) includes the administration of
high-dose TNF (3–4 mg/limb), interferon (IFN) gamma
(0.2 mg/limb), followed after 30 min by melphalan (10–
13 mg/l limb volume) (TIM-ILP) under mild hyperthermia
(38–40°C). In advanced melanoma and soft tissue sarcoma,
TIM-ILP produces extensive tumor necrosis in the absence
of significant local and systemic toxicity. This treatment,
we found, yields a very high complete response (CR) rate
in melanoma: 70 to 90% CRs in-transit metastases [8, 9]
(Fig. 3). In soft tissue sarcomas that are not extirpable, TM-
ILP produces 18 to 45% CRs and saves 80% of patients
from amputation [10, 11]. Angiographic and histological
studies revealed that its effect was due to selective
destruction of the tumor-associated vessels and that vessels
in normal tissues were spared [4] (Fig. 4). Human
recombinant (tasonermin) is now registered in Europe for
the treatment of advanced sarcoma of the limbs by ILP and
is also registered for in-transit melanoma metastases in
Switzerland.
These clinical results inspired experimental studies, in a
bedside-to-bench transfer, and it emerged that either
systemic or intratumoral application of TNF can increase
tumor microvasculature flow and permeability, and hence,
penetration of antibodies in a mouse colon cancer
xenograph model [5] (Fig. 5). In a rat limb soft tissue
sarcoma and osteosarcoma models, it was found that
perfusion with TNF selectively enhances melphalan and
doxorubicin penetration into tumors but not in muscle
tissue [12, 13] (Fig. 6). TNF also reduces IFP, as evidenced
by an increase in capillary filtration with no effect on
capillary tone [14]. Taken together, these results indicate a
selective effect of TNF on angiogenic endothelial cells.
The antitumor vasculature activity of TNF involves two
events. First, a rapid increase (within minutes) in the
permeability of the tumor vasculature, which favors the
selective accumulation of the chemotherapeutic agent in
the tumor tissue. The molecular mechanisms leading to
Fig. 1 Lack of doxorubicin penetration in sarcoma. Fischer rats
bearing syngeneic soft tissue sarcoma lung metastasis were
submitted to isolated lung perfusion with doxorubicin. After killing
the rats, their lungs were removed and analyzed by photonic and
fluorescence microscopy. Sample: sarcoma metastases surrounded
by normal lung tissue assessed by a (top) hematoxylin & eosin
staining, and b (bottom) fluorescence microscopy, demonstrating
that doxorubicin is localized in normal tissue, including the wall of
the tumor-feeding vessel, but not in the tumor itself [40]
Fig. 2 Schematic protocol description of TNF/IFNγ/melphalan-
isolated limb perfusion (TIM-ILP)
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enhanced permeability involve remodeling of the cyto-
skeleton and redistribution of the cell–cell adhesion
molecules PECAM-1 and VE-cadherin (reviewed in [7]).
Second, TNF elicits late (within hours) cytotoxic damage
to the tumor endothelial cells. Thus, the effectiveness of
this therapy is due to the sequenced administration of TNF,
followed 30 min later by melphalan for an additional time
of 60 min. TNF produces an early increase of vessel
permeability followed by a dual targeting: TNF induces
apoptosis of intratumoral angiogenic endothelial cells and
melphalan the apoptosis of tumor cells.
Our earlier ILP results in melanoma and sarcoma
showed that TNF can increase the therapeutic efficiency
of chemotherapeutic agents, even those of marginal
activity. For example, melphalan, a drug with no activity
in soft tissue sarcoma, can produce 20% CRs in large
sarcomas of the limbs when administered with TNF. These
events are presented in a tentative model (Fig. 7).
An explanation for this remarkable selectivity for
growing but not quiescent vascular tissues came from in
vitro and in vivo studies on endothelial biology. TNF, in
combination with IFN, deactivates the integrin αVβ3,
which is only expressed by angiogenic endothelial cells.
Because this integrin is essential for proliferation and
survival, treated angiogenic endothelial cells fail to adhere
to extracellular matrix proteins in the microvessels, and
they undergo massive apoptosis [15–17].
Fig. 5 TNF increases tumor blood vessels permeability. Subcuta-
neous LoVo human colon carcinoma xenografts were submitted to
intratumoral injection of 2 μg of TNF. Vascular permeability (VP) in
the tumors increased eight to tenfold 1 h after injection of TNF
compared to control tumors injected with saline. There was no
significant change in blood flow (BF) nor in vascular volume (VV).
(Reprinted with permission from S. Folli et al., Int J Cancer 53
(5):829–836. Copyright 1993 [5])
Fig. 3 Efficacy of TIM-ILP in melanoma. Male, 50 years old,
proximal melanotic melanoma in-transit metastases on left thigh.
a Day of TIM-ILP and b day 26 after perfusion. Nearly com-
plete response. Pigmentation indicates the area of high mel-
phalan concentration during ILP, fortunately corresponding to
tumor distribution
Fig. 4 Selective tumor vessel destruction by TIM-ILP. Female,
76 years old, extensive second recurrence of malignant fibrohistio-
cytoma in the anterior aspect of the leg. Angiogram before (left) and
7 days after (right) TIM-ILP. Histological assessment on large
biopsy taken 30 days after treatment confirmed complete response.
Twenty-three months after ILP, patient was alive with no sign of
recurrence nor metastasis. (Reprinted with permission from D.
Lienard et al., J Clin Oncol 10(1):52–60. Copyright 1992 [4])
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Is there a prospect for the systemic application of TNF?
Several attempts were made to improve the local delivery
of TNF in tumors and to decrease the systemic exposure to
the cytokine. Repeated intravenous injection of stealth
liposomes with TNF and doxorubicin in rats bearing soft
tissue sarcoma resulted in objective tumor response
without significant systemic side effects [18]. However,
half-life of stealth liposomes can exceed several days, a
condition of long-lasting low TNF concentration. There-
fore, the risk of tumor metastasis enhancement is to be
considered, although no such effect has been recorded in
this setting. To the best of our knowledge, no clinical trial
with this combination in liposomes has been performed.
Targeting TNF in tumor angiogenic vessels is an
appealing approach. The recent approach of using phage
display libraries led to the discovery of new targets for
antiangiogenesis strategies. It was recently possible to
isolate human antibody fragments that recognize altered
extracellular matrix proteins in oncofetal tissues and to find
peptides that can bind receptors expressed by angiogenic
endothelial cells in tumors. This allowed the development
of recombinant antibodies that specifically bind an isoform
of fibronectin (FN) and of a peptide that binds an isoform of
aminopeptidase N (CD13).
Anti-EDB FN/TNF fusion protein
The isoform containing the ED-B domain (B-FN) is highly
expressed in tumors, fetal tissues, and tissues undergoing
physiologic remodeling such as endometrium, ovary, and
wound healing tissues, but cannot be detected in normal
adult tissues. It was demonstrated that B-FN is especially
expressed in intratumoral angiogenic vessels (reviewed in
[19]). A single chain Fv antibody L19 (single-chain
variable fragment) specific for the B-FN isoform was
fused with monomeric TNF. The sequential administration
of L19/TNF followed by melphalan resulted in an
impressive tumor growth retardation while the same dose
of construct or melphalan alone showed poor efficiency
[20]. L19/TNF will be studied in phase I at Schering.
NGR-TNF
An isoform of aminopeptidase N (CD13) extensively
expressed by angiogenic tumor vessels binds peptides
containing the Cys-Asn-Gly-Arg-Cys motif [21]. A fusion
protein was designed where the N terminus of TNF is
coupled with the C terminus of the peptide: Asn-Gly-Arg
(NGR)-TNF. Moreover, a concentration of 106 times less
of NGR-TNF than TNF is still efficient. Evidence was
obtained that NGR-TNF improved the penetration of
melphalan and other drugs in tumors, which resulted in a
high therapeutic index [22]. It is interesting to note that a
critical therapeutic window was evidenced: The best
antitumor effect was obtained when drugs were injected
2 h after NGR-TNF, whereas it was lower after 1 or 3 h
[23]. This observation again illustrates the importance of
the therapeutic window. NGR-TNF is currently studied in
phase I at EORTC [24].
Fig. 7 Hypothetic model of the two distinct effects of TNF on
angiogenic endothelial cells after high dose of TNF administered by
ILP. Upon binding of TNF to TNF receptor p55/TNFR-1 and
activation of death domain, two different signaling pathways are
activated. Left: within 30 min of cleavage and activation, RIP
phosphorylations leads to I transcription factors, including inducible
NO synthase and NO production. The inflammatory response (see
text) leads to increased permeability and decreased interstitial
pressure. This results in increased drug penetration. Right: after 24 h,
FADD activation and loss of AKT activation—due to inhibition of
αVβ3 integrin—results in caspases activation and apoptosis of
angiogenic endothelial cells. In parallel, melphalan induces apopto-
sis of tumor cells (not shown)
Fig. 6 TNF increases chemotherapy penetration in tumors. Rats
bearing syngeneic soft tissue sarcoma on the leg were submitted to
ILP with melphalan with or without TNF. After the procedure,
measurements of melphalan were made in normal tissues and in the
tumors. While there was no change in normal tissues, there was a
sixfold increase of melphalan uptake in tumors. (Reprinted with
permission from Macmillan Publishers Ltd: J. H. de Wilt et al., Br J
Cancer 82(5):1000–1003. Copyright 2000 [12])
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Anti-gp240/TNF fusion protein
The recombinant fusion construct of single-chain anti-
melanoma antibody (scFvMEL)/TNF is composed of the
human TNF and a single-chain Fv recognizing gp240
present on 80% of melanoma [25] cases and 20% of
breast cancer cases. The fusion protein scFvMEL/TNF
was more cytotoxic to antigen-positive melanoma cells
than TNF alone and, in addition, was active against mela-
noma cells completely resistant to TNF itself. Coadmin-
istration of scFvMEL/TNF and chemotherapeutic agents
[vincristine, etoposide, cisplatin, 5-fluorouracil (5-FU),
and Adriamycin] in vitro for 72 h demonstrated synergis-
tic antitumor activity with Adriamycin or 5-FU and dem-
onstrated additive effects in combination with vincristine,
etoposide, or cisplatin [26].
Taken together, these three TNF-targeting preclinical
studies strongly suggest that it is possible to efficiently,
safely, and systemically administer TNF at a low dose if it is
targeted to angiogenic vessels or to a tumor. The efficiency
clearly resides in the improved efficacy of chemotherapy
because of improved intratumoral penetration.
Anti-VEGF
The VEGF family, especially VEGF-1 or VEGF-A, that is
now widely recognized as a major mediator of tumor
angiogenesis was first identified as vascular permeability
factor. Current approaches to blocking angiogenesis
include strategies that target VEGF-1, but little attention
has been paid to possible drawbacks, which may include
reduced penetration by chemotherapeutic agents adminis-
tered simultaneously or subsequently. In several animal
models, anti-VEGF antibodies or antisense VEGF therapy
reduce tumor growth but also consistently reduce intratu-
moral capillary permeability by as much as sixfold as
demonstrated by window chamber or contrast-enhanced
magnetic resonance imaging [27–29]. Vascular permeabil-
ity changes in response to VEGF result from the
accumulation of NO, which is produced mainly by
endothelial NO synthase [30]. Under pathological condi-
tions, including those that prevail in tumors, NO is
converted to peroxynitrite (ONOO−), which is responsible
for the enhanced vascular permeability [31]. This effect is
mediated partly through the activation of matrix metallo-
proteinases [32]. Therefore, anti-VEGF strategy is ex-
pected to decrease vessel permeability at a certain point in
time. This prediction was fortunately not fulfilled in the
combination of anti-VEGF (bevacizumab) and chemother-
apy in metastatic colorectal carcinoma treatment. It resulted
in better response and longer survival compared to
chemotherapy alone. The benefit in terms of overall
survival was 4.7 months, progression-free survival was
4.4 months, and objective response rate was increased from
38.8% with chemotherapy alone to 44.8% with the addition
of bevacizumab [33].
This success could well be to the lucky coincidence with
the “normalization window” described by R. Jain (Fig. 8)
[3]. However, a better-designed protocol that would take
this concept into consideration could well give better
results. Tumor vasculature is structurally and functionally
abnormal. Initially, the antivascular treatment improves the
structure and the function of tumor vessels. However,
aggressive or sustained antiangiogenic treatment may
eventually damage the vasculature, resulting in reduction
of blood supply and drug penetration. Therefore, the
normalization window would indicate that an antiangio-
genic treatment is optimal when it is given at a critical dose
and at a critical time. This concept was demonstrated using
anti-VEGFR-2 antibody and chemotherapy in an animal
model [34]. It seems that the current protocols combining
anti-VEGF to chemotherapy are not based on the rationale
of critical drug penetration and normalization window.
Rather, they are based on dual targeting of vessels and
tumor cells. It was demonstrated that a single infusion of
5 mg/kg of bevacizumab decreases tumor perfusion,
decreases microvascular density, decreases interstitial
fluid pressure, and increases pericyte coverage.
The same team that published the bevacizumab study
addressed the question of tumor microvascularization
changes in rectal cancer patients treated with a first dose
of bevacizumab alone [35]. They found tumor blood flow
and interstitial pressure reduction on day 12 after injection.
It is unfortunate that subsequent bevacizumab injections
were given simultaneously to chemotherapy. Indeed, the
authors did not take into account the critical effect of
bevacizumab on tumor vasculature and interstitial pressure.
It seems that a better rationale would be to first
administer anti-VEGF antibody and follow, at an adequate
time, with the administration of chemotherapy. A subse-
quent step will indeed be to allow the destruction of the
angiogenic vessels by repeated high dosage of anti-VEGF
antibody.
Fig. 8 Proposed model of tumor vascular normalization by R. Jain
when using a combination of antiangiogenic followed by cytotoxic
drugs. In case of too low dose or too early administration of
antiangiogenic drug, there is no effect on vessels. In the reverse
situation, normal tissues and vessels are damaged and cytotoxic drug
does not penetrate. The “normalization window” is the critical
situation where tumor vessels tend to reverse to a normal structure
and synergy between the antiangiogenic and cytotoxic drugs will be
possible. (Reprinted with permission from R. Jain, Science 307:58–
62. Copyright 2005 AAAS [3])
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This strategy could be also applied when using other
antiangiogenic agents. For example, sorafenib was found
to decrease the transfer of gadolinium from vessels to
tissues (Ktrans) [36]. If chemotherapy were given at this
point in time, an impediment to its tumor penetration must
be predicted.
Other compounds
Histamine is able to increase blood tumor permeability
[37]. ILP treatment of syngeneic rat sarcoma with hista-
mine—instead of TNF—increased tumor melphalan up-
take and improved the tumor response [38]. There was also
a reduction of vascular integrity in the surrounding tissue
after ILP treatment with histamine and melphalan com-
pared with melphalan alone. Because there was in vitro
evidence of tumor cell sensitization to melphalan, it seems
that this approach involves histamine effects on both
endothelial cells and tumor cells. A clinical trial is in
preparation in Rotterdam at Erasmus MC, Daniel den Hoed
Cancer Center.
A water-soluble analog of the antivascular agent
combretastatin A4, tubulin polymerization inhibitor, was
used in combination with docetaxel in a mammary
adenocarcinoma model in the mouse. Unlike combretasta-
tin that was found too toxic, the use of dosages as low as
13% of the highest nontoxic dose when administered
before, but not after, or simultaneously to docetaxel,
resulted in synergy with large therapeutic index [39]. A
randomized phase II was initiated at Sanofi/Aventis.
Conclusion
The current antitumor strategy paradigm based on the
synergism of empirical drug combinations is obsolete.
Instead, the design of protocols based on new pharmaco-
dynamic concepts, such as the “therapeutic window” and
the “normalization window”, should provide better effi-
ciency of cancer treatment as exemplified in ILP with TNF
and chemotherapy.
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